1-Methoxy-3,3-diacetoxypropan | 2806-82-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-Methoxy-3,3-diacetoxypropan
• 英文别名: (1-Acetyloxy-3-methoxypropyl) acetate
• CAS: 2806-82-8
• 化学式: C₈H₁₄O₅
• 分子量: 190.196
• InChiKey: YHTODHIMMAQGGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  13
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• COMBINATION THERAPY FOR INDUCING IMMUNE RESPONSE TO DISEASE
  申请人：IBC Pharmaceuticals, Inc.

  公开号：US20150231241A1

  公开（公告）日：2015-08-20

  The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for Trop-2 (EGP-1) and at least one binding site for CD3. The bispecific antibodies are of use for inducing an immune response against a Trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate. The methods may comprising administering the bispecific antibody alone, or with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-α), and/or checkpoint inhibitor antibodies. The bispecific antibody is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of Trop-2 + cancer cells. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC.
• DISEASE THERAPY WITH CHIMERIC ANTIGEN RECEPTOR (CAR) CONSTRUCTS AND T CELLS (CAR-T) OR NK CELLS (CAR-NK) EXPRESSING CAR CONSTRUCTS
  申请人：Immunomedics, Inc.

  公开号：US20160361360A1

  公开（公告）日：2016-12-15

  The present invention concerns CAR, CAR-T and CAR-NK constructs, preferably comprising a scFv antibody fragment against a disease-associated antigen or a hapten. More preferably, the antigen is a TAA, such as Trop-2. The constructs may be administered to a subject with a disease, such as cancer, autoimmune disease, or immune dysfunction disease, to induce an immune response against disease-associated cells. Where the constructs bind to a hapten, the subject is first treated with a hapten-conjugated antibody that binds to a disease associated antigen. Therapy may be supplemented by other treatments, such as debulking procedures (e.g., surgery, chemotherapy, radiation therapy) or coadministration of other agents. More preferably, administration of the construct is preceded by predosing with an unconjugated antibody that binds to the same disease-associated antigen. Most preferably, an antibody against CD74 or HLA-DR is administered to reduce systemic immunotoxicity induced by the constructs.
• COMBINATION THERAPY WITH T-CELL REDIRECTING BISPECIFIC ANTIBODIES AND CHECKPOINT INHIBITORS
  申请人：IBC Pharmaceuticals, Inc.

  公开号：US20170275375A1

  公开（公告）日：2017-09-28

  The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for a tumor-associated antigen (TAA) and at least one binding site for an antigen expressed on an effector T cell, NK cell, monocyte or neutrophil. The bispecific antibodies are of use for inducing an immune response against a TAA-expressing tumor. The methods may comprising administering the bispecific antibody in combination with one or more therapeutic agents such as antibody-drug conjugates, interferons (preferably interferon-α), and/or checkpoint inhibitor antibodies. The bispecific antibody is capable of targeting effector T cells, NK cells, monocytes or neutrophils to induce leukocyte-mediated cytotoxicity of cancer cells. The cytotoxic immune response is enhanced by co-administration of interferon, checkpoint inhibitor antibody and/or ADC. In preferred embodiments, the checkpoint inhibitor is a chimeric or humanized anti-PD1 antibody as described herein.
• US9682143B2
  申请人：——

  公开号：US9682143B2

  公开（公告）日：2017-06-20